clinical trial · NCT04070352
Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
University of Pittsburgh·—·withdrawn
Clostridium Difficile Infection (CDI)Fidaxomicin
brief summary
This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fidaxomicin
started
Aug 1, 2019
primary completion
May 1, 2023
completion
May 1, 2023
last updated
May 17, 2024
detailed description
This single site study will be a clinical research data base of patients hospitalized and diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to allow us to collect discard biological samples for testing and analysis in the investigators lab. An additional blood sample will be obtained if a clinically indicated bronchoscopy is performed as to measure the amount of medication in the BAL. We will also complete a medical record review will also occur.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol